Overview

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Anticoagulants
Dabigatran
Rivaroxaban